Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
Rhea-AI Summary
Amicus Therapeutics (FOLD) has scheduled its first quarter 2025 financial results conference call and audio webcast for Thursday, May 1, 2025, at 8:30 a.m. ET. The event will cover financial performance for Q1 ending March 31, 2025.
Participants must pre-register online to receive dial-in details and a personal PIN for phone access. A live webcast and presentation materials will be available through the Investors section at ir.amicusrx.com, with recommended registration 15 minutes before the call. An archived version and slides will be accessible post-event on the company website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FOLD declined 1.76%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When will Amicus Therapeutics (FOLD) release Q1 2025 earnings?
How can investors join the Amicus Therapeutics Q1 2025 earnings call?
Where can I find the replay of FOLD's Q1 2025 earnings call?
What period will FOLD's upcoming earnings report cover?
